Sunomix Biosciences & it’s partners are the industry leading expert in antibody, protein engineering and can utilise our experience to provide comprehensive services for the conjugation and characterisation of Antibody-Drug Conjugates. With years of experience in the a variety of cell based bioassays and binding assays, we provide comprehensive expertise to support the development of antibody-drug conjugate products for all phases of drug development from discovery through to GMP manufacturing.

Antibody-drug conjugates (ADCs) are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. ADCs are complex molecules composed of an antibody linked, via a stable, chemical linker to a biological active cytotoxic (anticancer) payload or drug. Therapeutic monoclonal antibodies may be conjugated with a wide array of different molecules. Using the highly specific and selective targeting mechanism of the antibody, the ADC can discriminate with great sensitivity between normal and cancerous tissues, allowing a significant reduction in the therapeutic dose of the drug reducing the toxic side effects to patients.

We provides a wide range of services to support the characterization of various forms of antibodies that can be applied to antibody drug conjugates, which including almost all the monoclonal and engineered antibodies, peptides and proteins. Our scientists are pleased to offer site-specific antibody-drug conjugation services based on traditional strategy as well as unique conjugation strategy developed at our labs. Small drugs or toxins can be conjugated to an antibody at a specific site away from the antigen binding site.

We offer a series of Antibody-Drug Conjugation Services

Conjugation of drug or toxin to antibody
Protein-drug bio-conjugates
Characterization of Antibody-Drug Conjugates bysize exclusion chromatography and UV/Vis spectrometry
Binding and Immunoassays

To find out more details about this custom service, Please request a quote today.